Penetration of vancomycin into epithelial lining fluid in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5507-5511

  Lodise, Thomas P ^a   Drusano, George L ^b,e   Butterfield, Jill M ^a   Scoville, Joshua ^a   Gotfried, Mark ^c   Rodvold, Keith A ^d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONTE CARLO METHOD; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; EPITHELIUM; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; VANCOMYCIN; YOUNG ADULT;

EID: 81555224256     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00712-11     Document Type: Article

References (22)

1. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
2. Cars, O., and S. Ogren. 1985. Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scand. J. Infect. Dis. Suppl. 44:7-15. (Pubitemid 15056604)
3. Cruciani, M., et al. 1996. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. 38:865-869. (Pubitemid 26413723)
4. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134. (Pubitemid 9104986)
5. Eli Lilly and Company. 2001. Vancocin® HCl prescribing information. Eli Lilly and Company, Indianapolis, IN.
6. Georges, H., et al. 1997. Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 16:385-388. (Pubitemid 27271829)
7. Kollef, M. H., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and R. G. Wunderink. 2004. Clinical cure and survival in Gram-positive ventilatorassociated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30:388-394. (Pubitemid 38375611)
8. Kollef, M. H., et al. 2005. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854-3862. (Pubitemid 43062645)
9. Lamer, C., et al. 1993. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37:281-286.
10. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. Proceedings, Fourteenth IEEE Symposium on Computer-Based Medical Systems. 26-27 July 2001, Bethesda, MD.
11. Lodise, T. P., Jr., M. Gotfried, S. Barriere, and G. L. Drusano. 2008. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 52:2300-2304. (Pubitemid 351915656)
12. Lodise, T. P., B. Lomaestro, J. Graves, and G. L. Drusano. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52: 1330-1336. (Pubitemid 351521995)
13. Lodise, T. P., N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
14. Mahmood, I., and J. Duan. 2009. Population pharmacokinetics with a very small sample size. Drug Metabol Drug Interact. 24:259-274.
15. Mohr, J. F., and B. E. Murray. 2007. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542. (Pubitemid 46871498)
16. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942. (Pubitemid 39447034)
17. Muscedere, J. G., C. M. Martin, and D. K. Heyland. 2008. The impact of ventilator-associated pneumonia on the Canadian health care system. J. Crit. Care. 23:5-10. (Pubitemid 351400351)
18. Rodvold, K. A., et al. 2009. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob. Agents Chemother. 53:3294-3301.
19. Rubinstein, E., S. Cammarata, T. Oliphant, and R. Wunderink. 2001. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32:402-412. (Pubitemid 32173626)
20. Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
21. Wunderink, R. G., et al. 2008. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134:1200-1207.
22. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet Biopharm. 6:165-175. (Pubitemid 8384279)